GeneDx Holdings Corp. (WGS) Slid as Revenue Fell Short of Expectations

2 months ago 27

Soumya Eswaran

Tue, July 21, 2026 astatine 9:04 AM CDT 3 min read

Fred Alger Management, an concern absorption company, released its "Alger Small Cap Focus Fund" second-quarter 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. U.S. equities experienced a beardown betterment successful Q2 2026, with the S&P 500 Index gaining 15.2%, marking its champion 4th since 2020. A ceasefire betwixt the United States and Iran and accelerated concern successful artificial quality (AI) fueled marketplace optimism successful the quarter, driving the Information Technology and Industrials sectors guardant portion Energy and Utilities lagged owed to falling lipid and state prices. In June, the Federal Reserve maintained dependable involvement rates, but the gathering had a hawkish tone. As AI transitions into its agentic phase, opportunities are identified wrong sectors adopting the technology. The Alger Small Cap Focus Fund's Class A shares outperformed the Russell 2000 Growth Index successful the quarter, driven by beardown performances successful the Industrials and Health Care sectors, portion Financials and Consumer Discretionary detracted from the performance. In addition, delight cheque the Fund's apical 5 holdings to cognize its champion picks successful 2026.

In its Q2 2026 capitalist letter, Alger Small Cap Focus Fund highlighted GeneDx Holdings Corp. (NASDAQ:WGS). GeneDx Holdings Corp. (NASDAQ:WGS) is simply a genomics institution that offers precocious exome and genome sequencing for pediatric and uncommon illness diagnostics. On July 20, 2026, GeneDx Holdings Corp. (NASDAQ:WGS) closed astatine $60.65 per share, reflecting a marketplace capitalization of $1.80 billion. GeneDx Holdings Corp. (NASDAQ:WGS) posted a one-month instrumentality of 4.42%, portion its shares mislaid 25.03% implicit the past 52 weeks.

Alger Small Cap Focus Fund stated the pursuing regarding GeneDx Holdings Corp. (NASDAQ:WGS) successful its Q2 2026 capitalist update:

"GeneDx Holdings Corp. (NASDAQ:WGS) is simply a specialty genomics laboratory focused connected delivering analyzable familial tests, including full exome and genome sequencing, to diagnose pediatric uncommon diseases. The institution possesses a broad and proprietary database of familial information that enables it to present superior diagnostic yields comparative to competitors and alternate investigating modalities, creating a meaningful competitory vantage successful a highly specialized market. Shares detracted from show aft first-quarter results missed gross expectations connected softer mean reimbursement rates and weakness successful non-core segments. While underlying exome and genome trial volumes grew 33% twelvemonth implicit year, absorption lowered full-year guidance, weighing connected capitalist sentiment."

Read Entire Article